Compare EOG Resources Inc (EOG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? EOG Resources Inc trades at $154.2 (market cap $80.34B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: EOG Resources Inc is far larger — about 16.5× Travere Therapeutics Inc. Common Stock's market cap, and EOG Resources Inc pays a 2.66% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EOG | TVTX | |
|---|---|---|
Market Cap | $80.34B | $4.88B |
Volume | 2,309,813 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $154.19 | $67.52 |
52-Week Low | $101.78 | $26.79 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $83.69B | $5.01B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $154.19, up 2.45% today, with a bullish technical outlook and strong fundamentals. The stock has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations. Valuation ratios are attractive, including a P/E of 11.92 and EV/EBITDA of 6.02. Recent news highlights robust operational execution and a CFO transition.
The outlook remains positive, supported by analyst consensus of a $165 price target and 59% buy ratings. Key risks include oil price volatility and capital expenditure trends. Upside potential hinges on sustained earnings growth and disciplined capital allocation amid energy market fluctuations.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
